TG Therapeutics Q3 revenue up on strong demand, raises 2025 forecast

TG Therapeutics

03/11/2025 12:10

Overview

TG Therapeutics Q3 2025 revenue was $161.7 mln, driven by BRIUMVI sales

Company raises 2025 global revenue target to $600 mln, BRIUMVI U.S. target to $585 mln

Completed $100 mln share repurchase, authorized additional $100 mln program

Outlook

TG Therapeutics raises 2025 global revenue target to $600 mln

Company increases 2025 BRIUMVI U.S. net revenue target to $585 mln

Company cites strong market demand for raising revenue guidance

Result Drivers

BRIUMVI SALES GROWTH - BRIUMVI U.S. net revenue grew 84% year-over-year, driven by strong market demand

INTERNATIONAL EXPANSION - BRIUMVI approved in multiple new markets, including EU and Australia

PIPELINE ADVANCEMENT - Ongoing Phase 3 trials for subcutaneous ublituximab and simplified BRIUMVI dosing

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$161.7 mln
Q3 Net Income
$390.89 mln
Q3 Operating Income
$29.36 mln


Press Release: ID:nGNX3dpYmY

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)